Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH-26
- Development stage
- Unknown
- Lead developer
- WPP
- Administration
- Oral
01
Overview
**CH-26** is a commercially listed oral homeopathic remedy from Curanter Homeo, presented on the company's product listing as \"CH - 26 (Osteoporosis Drop).\" The available public product listing does not disclose its active ingredients, homeopathic dilutions, pharmacological target, mechanism of action, clinical evidence, regulatory approval status, or formal development program. It is therefore best characterized as a retail homeopathic product marketed for osteoporosis-related use rather than a clinically characterized drug candidate. ([curanter.com](https://curanter.com/))
- Other names
- Osteoporosis Drop
Beyond the preview
Go deeper on CH-26.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH-26.